Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MRC is like a porch pirate who tries to steal your package and finds out it is a Cologuard stool sample.
Does anyone know where TerraPharma got this excerpt on the judge's opinion from? It seems to be from today.
$AMRN vs Generics (defendants) Judge: pic.twitter.com/bow5Z8H65r
— TerraPharma (@TerraPharma1) December 17, 2019
I like the way his buyout target of 42 was exactly 50% over their price target of 28. I'm sure a lot of number crunching and research went into that.
Well that just shows how little their opinion is worth.
GS also upgrades their M&A value for AMRN to $42.00
$AMRN Goldman upgrades M&A value to $42 @TerraPharma1 @BullStoneTrade pic.twitter.com/NcJKwZo16u
— StonesCapital (@StonesCapital) December 16, 2019
TerraPharma is saying 2:15. You know Meg Tirrell is going to lean hard on the buyout question - she always does. C'mon JT, throw us a frikkin bone here.
If FFS were still here he would probably point out that we just did an almost exact 50% retrace from the bounce up from the pre adcom briefing docs run which started around 18 and went up 8 to about 26 then back down 4 to 22. For whatever that's worth.
Thanks! I'll give it a try.
I just tried to look at the Mason video again and the link that is on the Amarin website page about Vascepa:
https://investor.amarincorp.com/static-files/eaf1ff2e-e014-4180-880b-058278dffb06
has a link to the Mason video (the second web link listed on this page)
but it does not work anymore.
Does anyone have a valid link to that Mason video? I watched it awhile back and thought it was the best presentation in understanding the superiority of V over fish oil and explaining the MOA.
Okay. So are most doctors going to read about the study and think V only works with statins or are they going to be able to read between the lines and figure out like most people on this board that it has a benefit on its own? Will Amarin even try to educate them on that? Maybe evaporate will help on that.
I usually lie to my doctors and tell them I don't drink and never smoked. I always figured the insurance company would use it against me to charge me more or deny me something. My current plan says they will charge me an extra $100 a month unless I swear that I don't smoke. (I don't now but did as a teenager)
You're right. I don't see the risk factors on the label either, I was just copying them from a previous post from someone else and assumed it was from the label.
I think the worst thing that happened to him was guessing right on shorting AMRN at about $23 before AHA and covering a couple of weeks later at $16 or so. He became convinced of his own super human contrarian visions. Surely he's blown that wad by now.
SRPT just got early approval. Up $24 AH. AMRN next?
https://newsfilter.io/articles/sarepta-therapeutics-announces-fda-approval-of-vyondys-53-golodirsen-injection-for-the-treatment-of--f710df5a1f4a82ecce6a7bbf5058a5c4
Reminds me more of a Martin Shkreli wannabe. This is straight out of his playbook. Hope Stevie says hi to Marty when he gets inside. He better watch out though, I hear Marty has been working on his physical conditioning and can now do up to 7 pushups!
Yeah, you forgot Europe snuffing out our competition. I'm getting tired of winning - or keeping up with all the ways we are winning.
That Sharma guy who wrote the SA article saying he was going to short AMRN down to 5 is claiming the new ADA SOC announcement has nothing to do with Amarin. He's catching hell on twitter - "Don't get caught with your pants down again, that's how you lost your license."
At this point over 800K shares traded AH and up another $.82. I think it will be a busy day tomorrow.
Quite frankly, this is the news I was expecting for the ACC conference, or something similar that would lead to this. I think this may have been what the market was expecting also but did not get. It may be why the share price dropped so much since then. But to get the ADA to declare this as SOC so quickly is even more than I expected.
New PR out about the papers being presented:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190304:nGNX5JLBtp
If it's considered bad news for Pfizer then it makes sense they would want to announce it on a Friday.
Maybe it's a precondition for accepting late breaking presentations like it was for the AHA. Maybe that's the way it's supposed to be done to get the most exposure.
Options expiration Friday tomorrow. The calls with the most open interest are at 18.00 - imagine that. (but only about 2000)
TSRO was at $25 a couple of weeks ago when the price jumped $10 in one day. That must have been when the first rumors came out. It's a triple from there.
Okay, thanks Tasty.
What the heck is this that was just filed?
http://archive.fast-edgar.com//20181129/AW29H22CZ22YM2Z2222A2WXQUM9LZZ22D2A2/
Retiring an old shelf agreement? Paying off an old debt?
The form 424B5 is out. It says $16.88 per share for 12,777,778 shares.
http://archive.fast-edgar.com//20181128/AE22N62FZW2RJZZU222M2ZXMPANA4Z22Z2A2/
I think the Spirit of Christmas Future must have visited Jerome Powell and shown him what the economy would look like if he didn't ease up on rates. Dow was up 450. This rising tide should help lift our boat also and encourage the shorts to cover. Yes Virginia, there is a Santa Rally.
I remember reading on Zero Hedge about some trader who was able to manipulate the market by spending a few hundred thousand dollars on deep out of the money puts and tricking the robot algos into selling. Then he made a few million shorting the shares. Not sure if that is possible with a small stock like AMRN, or if it is even possible at all.
Now there's a gap up above in the 19s from this morning.
LOL! "Fake News" Herper
Here's a cheat sheet someone more knowlegeable than me posted a week or two ago. The most debatable point to me would be the PE. Don't forget about supply limitations. CEO only coralled enough to support $1B revenue before results were known.
rounded numbers, ~$25 share price per 1M patients per year
revenue per capsule: $1.00
capsules/day: 4
revenue per patient per year: $1,500
patients per year: 1M
annual revenues: 1.5B
net profit margin: 30%
EBITDA: $450M
fully diluted shares outstanding: 373M
earnings/share: $1.20
P/E multiplier: 20
share price: $24
market capitalization: $9B
kilograms of API per year: 1,500,000
metric tonnes of API per year: 1,500
Real world revenue as reported in the last quarterly earnings report are more like $1,500 per patient per year. Maybe someone else can answer why - coupons, insurance deals? Anyway I believe that's what HDG and others are counting on.
At the Jefferies conference JT said that even the most enthusiastic doctors are not going to call all of their patients in for immediate special consultations to switch them over to Vascepa. They will wait until the next regularly scheduled 6 month or annual appointment to discuss it with them. So it will take a full year to get all their patients started.
He is also still guiding toward FDA approval for the expanded indication to be at the end of 2019 and full insurance coverage to follow after that. I believe marketing replied to a question from someone here that they will not change their advertising to target the expanded population until after FDA approval.
Having said that, the market should start valuing the stock based on the billions they know will be made in 2-5 years, just like they are giving AMZN a PE of 92 now. Everyone just assumes Bezos really is Dr. Evil and will take over the world.
Wouldn't any change in Baker Bros holdings have to be reported in SEC filings within 48 hours? If they did something big Tuesday we would have known by now.